The division will comprise Fujifilm Diosynth Biotechnologies USA, Inc., FUJIFILM Diosynth Biotechnologies UK in the UK, and Kalon Biotherapeutics (currently FUJIFILM Diosynth Biotechnologies Texas) acquired in 2014, and strives for combined sales of 100 Bill. Yen in FY 2023.

Fujifilm news release, Feb. 28, 2017